Globalworld globe
United Kingdom
North America
Europe
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
    • Medical Devices
    • Veterinary
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

News

POST TRUMP: Business as usual – MVP signs a Respiratory deal and receives first order

Nov 13, 2016Mark EdwardsNews

14 November 2016

POST TRUMP: Business as usual – MVP signs a Respiratory deal and receives first order

Medical Developments International Limited (ASX: MVP) is delighted to announce that it has finalised a distribution deal with McKesson Corp. for the distribution of its range of ‘Space Chamber’ anti-static Respiratory Devices in the United States of America (USA). At the same time as concluding the agreement, McKesson placed its first order for stock which will be delivered by the end of December.

For details relating to the full ASX release, please click on the following link: mvp-signs-a-usa-respiratory-deal

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • Green Whistle gets the Green Light – FDA clears US Penthrox clinical trial

    2 March 2022 ASX ANNOUNCE...

  • MVP FY22 Half Year Results Investor Presentation

    25 February 2022 ASX anno...

  • MVP FY22 Half Year Report and Accounts

    24 February 2022 ASX Anno...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me

Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: [email protected]
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: [email protected]

Email Newsletter